OSE Immunotherapeutics SA (LON:0RAD)

OSE Immunotherapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 2, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	98	130	70	109	158	116
Market Cap Growth	-24.80%	85.55%	-36.14%	-30.57%	36.38%	147.04%
Enterprise Value	86	103	95	114	155	113
Last Close Price	4.39	6.03	3.74	6.16	8.49	6.49
PE Ratio	3.15	4.19	-	-	-	-
PS Ratio	1.42	1.88	36.17	6.74	7.14	12.38
PB Ratio	1.85	2.46	3.51	3.78	3.92	2.10
P/TBV Ratio	1.85	2.46	3.53	3.80	3.93	2.10
P/FCF Ratio	2.44	3.24	-	-	-	-
P/OCF Ratio	2.44	3.24	-	-	-	-
EV/Sales Ratio	1.19	1.50	49.07	6.99	7.01	12.09
EV/EBITDA Ratio	2.23	2.84	-	-	-	-
EV/EBIT Ratio	2.28	2.86	-	-	-	-
EV/FCF Ratio	2.16	2.58	-	-	-	-
Debt / Equity Ratio	0.72	0.72	1.99	1.37	0.78	0.32
Debt / EBITDA Ratio	1.03	1.03	-	-	-	-
Debt / FCF Ratio	0.95	0.95	-	-	-	-
Asset Turnover	0.81	0.81	0.03	0.19	0.27	0.11
Quick Ratio	3.29	3.29	1.40	1.97	2.36	2.57
Current Ratio	3.46	3.46	1.62	2.29	2.64	2.82
Return on Equity (ROE)	86.29%	86.29%	-82.69%	-44.10%	-30.85%	-27.62%
Return on Assets (ROA)	26.54%	26.54%	-16.53%	-11.93%	-10.45%	-12.77%
Return on Capital (ROIC)	30.59%	30.59%	-19.65%	-14.21%	-12.53%	-15.73%
Return on Capital Employed (ROCE)	42.20%	42.20%	-36.30%	-24.50%	-19.50%	-22.90%
Earnings Yield	31.71%	23.88%	-28.56%	-14.39%	-8.98%	-12.83%
FCF Yield	40.96%	30.84%	-24.56%	-15.01%	-5.54%	-15.32%
Buyback Yield / Dilution	-31.11%	-31.11%	-5.58%	-2.05%	-16.71%	-4.46%

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.